Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Market Analysis
Adjunctive cancer therapies market expected to top $24.5 billion by 2010
May 18th, 2006
With more than 10 million new cases of cancer diagnosed throughout the world every year, revenues from adjunctive therapies used to relieve the side effects of both primary cancer treatments and the disease itself are growing at an annual rate of 7.4% and are expected to reach $24.5 billion by 2010. According to "The Global Market for Adjunctive Therapies in Cancer," a new study from Kalorama Information, 2005 revenues for therapies addressing nausea, anemia, pain, and infections, among others, exceeded $17 billion. Indeed, from 2003 to 2005, the market grew by nearly 15%, primarily due to strong sales of biological response modifiers, and nausea, emesis, and...
Source: Biotech Business Week (2006-05-18)
|
